Minerva Neurosciences reported $3.03M in Selling and Administration Expenses for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US $ 96.68M 9.23M
Adma Biologics ADMA:US $ 17.67M 1.88M
ALKERMES ALKS:US 145.05M 15.36M
AstraZeneca AZN:LN 3.06B 1.03B
Biocryst Pharmaceuticals BCRX:US $ 34.28M 1.1M
Bristol Myers Squibb BMY:US $ 1.83B 523M
Dynavax Technologies DVAX:US $ 31.46M 2.66M
Eli Lilly And LLY:US $ 1.56B 34.1M
Esperion Therapeutics ESPR:US $ 30.38M 5.29M
GlaxoSmithKline GSK:LN 2.68B 227M
Halozyme Therapeutics HALO:US $ 13.83M 60K
IONIS PHARMACEUT IONS:US $ 34.13M 3.47M
Johnson & Johnson JNJ:US $ 5.94B 1.22B
Marinus Pharmaceuticals MRNS:US 11.74M 1.12M
Merk MRK:US $ 2.3B 518M
Minerva Neurosciences NERV:US $ 3.03M 398.63K
Novartis NOVN:VX 3.5B 486M
Novavax NVAX:US $ 95.99M 11.78M
Takeda 4502:JP 223.43B 7.65B
Vanda Pharmaceuticals VNDA:US $ 40.85M 7.4M